lunes, 29 de octubre de 2018

Cystic Fibrosis Weekly Update

Contents:

#NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach
#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Phase 2 Study Shows

#NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach

Oct 29, 2018 07:30 am | Larry Luxner

With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or Republicans stay in control, no matter […]
The post #NORDSummit – Major Issues on Table for Rare Disease Patients in US as Midterm Elections Approach appeared first on Cystic Fibrosis News Today.

#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Phase 2 Study Shows

Oct 29, 2018 07:00 am | Ana Pena

Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency and delays the onset of pulmonary exacerbations in CF patients, results from a Phase 2 study show. Patients with better lung function benefited most, with a 96% higher chance of being free of exacerbations after 48 weeks of […]
The post #NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Phase 2 Study Shows appeared first on Cystic Fibrosis News Today.